Welcome to our dedicated page for 10X Genomics SEC filings (Ticker: TXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for 10x Genomics, Inc. (NASDAQ: TXG), a life science technology company specializing in single cell and spatial biology. Through these filings, investors and researchers can review the company’s regulatory disclosures, including annual and quarterly reports and current reports on material events.
10x Genomics’ Class A common stock is registered on The Nasdaq Stock Market LLC under the symbol TXG, as noted in its Form 8-K filings. The company uses SEC filings, along with its website, press releases, public conference calls, webcasts and social media accounts, as channels for disclosing information and for complying with Regulation FD. Form 8-K filings have addressed topics such as quarterly financial results and changes in certain executive roles.
Key SEC documents for TXG include annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed information about revenue by product type and geography, gross margin, operating expenses, cash and marketable securities, and risk factors. Current reports on Form 8-K provide timely updates on specific events, such as earnings releases or leadership changes. Together, these filings give a structured view of how 10x Genomics’ single cell and spatial biology business is performing and evolving.
On Stock Titan, users can view TXG filings as they are made available from EDGAR and use AI-powered summaries to interpret complex sections, such as revenue breakdowns, operating results and risk disclosures. Filings related to topics like license and royalty revenue, services, and geographic revenue distribution can be examined to understand the company’s financial profile. This page also offers convenient access to insider and governance-related filings, helping users track corporate developments over time.
10x Genomics, Inc. CEO Serge Saxonov reported open‑market sales of 15,000 shares of Class A Common Stock. He sold 10,000 shares on March 23, 2026 at a weighted average price of $19.1297 per share and 5,000 shares on March 24, 2026 at a weighted average price of $19.5223 per share.
The filing states these transactions were executed under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 29, 2025. After the sales, he directly holds 1,172,273 shares of Class A Common Stock and also has significant additional indirect and Class B holdings held through various trusts where he serves as trustee, with each Class B share convertible into one Class A share.
10X Genomics Inc Schedule 13G/A amendment shows The Vanguard Group reporting zero shares beneficially owned of Common Stock after an internal realignment effective January 12, 2026. The filing states Vanguard's subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.
The filing records 0 shares beneficially owned and 0% of the class, with no sole or shared voting or dispositive power listed. The signature block is by Ashley Grim, Head of Global Fund Administration dated 03/25/2026.
10X Genomics Inc ownership filing: The Vanguard Group filed an amendment to a Schedule 13G reporting 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing states Vanguard and related managed accounts have rights to dividends or sale proceeds but hold no >5% interest.
FMR LLC reports beneficial ownership of 18,543,561.62 shares of Class A common stock of 10x Genomics, Inc. as of February 27, 2026, representing 15.6% of the Class A shares. The filing notes that 892,772 shares of Class B common stock held by Fidelity-advised investment companies are included in this figure and are convertible into Class A on a 1:1 basis.
The filing also lists Abigail P. Johnson with shared reporting authorities tied to the same 18,543,561.62-share position. The schedule states: "Assuming the conversion of all outstanding shares of Class B Common Stock into Class A Common Stock, the 18,543,561 shares ... would represent 14.5153% of the outstanding Class A Common Stock."
10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported planned share sales and a gift of stock. On March 2, 2026, he sold a total of 16,152 shares of Class A common stock in open-market transactions at weighted average prices of $22.6690 and $23.1781, effected under a Rule 10b5-1 trading plan adopted on November 29, 2025. On March 3, 2026, he made a bona fide gift of 2,750 shares at no consideration. After these transactions, he directly held 1,200,917 shares of Class A common stock, and also had indirect holdings of 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust, for which he serves as trustee.
10x Genomics, Inc. reported that Chief Executive Officer Serge Saxonov acquired an equity award in the form of restricted stock units covering 157,895 shares of Class A Common Stock at a stated price of $0.00 per share on February 26, 2026.
Each RSU represents a right to receive one share of Class A Common Stock upon vesting. According to the terms, 1/12 of the RSUs vest on each quarterly anniversary starting from February 21, 2026, as long as he continues as a service provider on each vesting date.
The filing also lists indirect holdings of Class A Common Stock held by the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust, for which Saxonov serves as trustee, totaling separate positions of 27, 213,250, and 58,000 shares respectively.
Hindson Benjamin J. reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics, Inc. reported that director and officer Benjamin J. Hindson received a grant of 88,816 restricted stock units (RSUs) linked to its Class A Common Stock at a stated price of $0.00 per share. Each RSU represents a right to receive one share upon vesting.
According to the award terms, 1/12 of the RSUs will vest on each quarterly anniversary starting on February 21, 2026, as long as Hindson continues as a service provider through each vesting date. After this grant, his directly held Class A Common Stock, including RSUs, totals 513,595 shares.
Taich Adam reported acquisition or exercise transactions in this Form 4 filing.
10x Genomics Chief Financial Officer Adam Taich received an equity award of 106,579 shares of Class A Common Stock in the form of restricted stock units (RSUs). The award was granted at no cash cost per share and increases his directly held beneficial ownership to 394,996 shares.
The RSUs vest over time, with 1/12 of the units vesting on each quarterly anniversary starting from February 21, 2026, as long as he continues as a service provider through each vesting date. This structure is designed to align his compensation with the company’s long-term performance and retention.
TXG affiliate files a Form 144 proposing sales of Class A Common stock. The filing lists multiple vested RSU lots tied to issuer vesting events, including 16,152; 4,879; 3,265; 3,723; 8,156; and 4,977 shares. The filing lists JP Morgan Securities LLC as broker and Nasdaq as the market.
10x Genomics, Inc. director Sarah A. Teichmann reported an open-market sale of 7,579 shares of Class A Common Stock at $19.41 per share. After this transaction, she directly holds 26,780 shares. The sale was executed under her pre-arranged Rule 10b5-1 trading plan.